Skip to main content
Equibles
COO logo

COO · Cooper Companies, Inc.

Track COO — free

Use COO with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research COO.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$56.91 -0.50 (-0.87%) At close · Oct 2
S&P 500 member Russell 1000 member Rebalance outlook locked
Market Cap
$10.86B
Shares
190.16M
Volume · Oct 2 3.31M Avg daily vol (3M) 3.06M

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$56.91 Open$57.52 Day$56.72–57.69 52W close$53.27–84.32 Avg vol 30d4.3M Short int10.0M · 5.3% float · 1.9d Short vol38% Last earningsSep 9, 2026 DataJan 2020–Oct 2026 Filing10-Q · Sep 9

Up next

Next earnings call
Dec 12, 2026 Est · unconfirmed · in 10 wks
Latest filing: 10-Q
filed Sep 9, 2026
Q3 2026 earnings call transcript
call held Sep 9, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$4.24B
Trailing 12 months
Net income (TTM)
$570.30M
Trailing 12 months
Revenue growth YoY
+0.6%
Year over year
Operating margin
12.8%
Trailing 12 months
P / E (TTM)
19.5
Trailing earnings · reciprocal yield 5.1%
FCF yield
6.2%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
−$2.39B
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
-3.3%
Year over year · fewer shares
Price change (1Y)
-17.7%
Trailing year
Short interest
5.3%
Latest settlement · 1.9 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Very Weak Sentiment Neutral Fundamentals Strong Quant / Vol Moderate
Market backdrop VIX 15.3 · calm Equity put/call 0.58
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −20%
below
Price vs 50-day avg −15%
below
RSI (14) 38
neutral
MACD trend Positive
52-week position 12%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −19%
trailing
6-month return −21%
trailing
YTD return −31%
this year
Relative strength −33%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $67 › 200d $71 — 200d above 50d
Institutional flow Distributing
3 of 681 funds reported for Sep 30 · net -3.4K sh shares
Insider flow Accumulating
Net +$1.9M over 90 days · 0% sells
Short interest Rising
5.26% of float · ▲ +14.0% MoM · 1.9 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
681 holders — near 3-yr high, broad support
Squeeze score 51
elevated · 0–100
Fundamentals
Strong
Revenue growth +18%
Y/Y
Gross margin 106%
contracting
EPS growth −5%
Y/Y
Free cash flow $433.7M
Valuation P/E 19.6
below peers
Buyback $1.5B
remaining
Balance sheet $2.4B
net debt
Quant / Vol
risk profile
Moderate
Volatility 32%
annualized · 1-yr
Max drawdown −37%
past year
ATR 3.3%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 5 of last 6
Latest guidance · from the 8-K filed Sep 9, 2026
Fiscal fourth quarter 2026
Total revenue Initiated $1.06B – $1.08B
prior qtr $1.07B midpoint +0.2% QoQ
CVI revenue Initiated $692M – $706M
CSI revenue Initiated $364M – $374M
Non-GAAP diluted EPS Non-GAAP Initiated $1.05 – $1.09
Fiscal 2026
Total revenue Lowered $4.23B – $4.25B
Jun 4, 2026 $4.29B – $4.32B changed to Sep 9, 2026 $4.23B – $4.25B
prior FY $4.09B midpoint +3.6% Y/Y
Non-GAAP diluted EPS Non-GAAP Lowered $4.51 – $4.55
Jun 4, 2026 $4.58 – $4.66 changed to Sep 9, 2026 $4.51 – $4.55
fiscal years 2026 through 2028
Long-term free cash flow objective at least $2.2B
Guided vs delivered · last 6 settled
Total revenue Fiscal 2024
guided $3.86B – $3.91B
$3.9B In line
Total revenue Fiscal 2023
guided $3.51B – $3.57B
$3.59B Beat +1.5%
Consolidated revenues fiscal 2022
guided $3.03B – $3.09B
$3.31B Beat +8.1%
EPS Q1
guided $3.00 – $3.10
$1.91 Miss −37.4%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Sell
3 · 3 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−20% Bearish
Price vs 50-day avg
−15% Bearish
RSI (14)
38 Neutral
MACD trend
Positive Bullish
52-week position
12% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $67 › 200d $71 — 200d above 50d
Institutional flow Distributing
3 of 681 funds reported for Sep 30 · net -3.4K sh shares
Insider flow Accumulating
Net +$1.9M over 90 days · 0% sells
Short interest Rising
5.26% of float · ▲ +14.0% MoM · 1.9 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
681 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $53 Now $57 · 12% Range high $84
vs 200-day avg -20% vs 50-day avg -15%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Free cash flow $273M Third Quarter 2026 —
Non-GAAP diluted EPS non-GAAP $1.15 Third Quarter 2026 —
Non-GAAP gross margin non-GAAP 67% Third Quarter 2026 —
Non-GAAP net income non-GAAP $221.5M Three Months Ended July 31 —
Non-GAAP operating income non-GAAP $280.7M Three Months Ended July 31 —
Non-GAAP operating margin non-GAAP 26% Third Quarter 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Medical Instruments & Supplies — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
COO
Cooper Companies, Inc.
this stock
$10.86B -30.6% +18.4% 19.6 5.3%
ISRG
Intuitive Surgical Inc
 $143.14B -30.8% +20.5% 46.5 2.3%
BDX
Becton Dickinson & Co
 $49.57B — +8.2% — 4.2%
MDLN
Medline Inc.
 $45.62B -15.2% +11.5% — 3.1%
RMD
Resmed Inc
 $32.02B -9.1% +13.4% 21.3 9.8%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
681
% held
110.3%
Reported
3 of 681
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
615
View
Short & Settlement
Short Interest Rising
Shares short
10.0M
Days to cover
1.9d
Change
+1.2M sh
View
Short Volume
Short vol %
38%
As of
Oct 2, 2026
Short Total
View
Fails to Deliver
FTD shares
2.5K
Value
$156.1K
As of
Sep 10, 2026
View
Off-Exchange
Off-exchange %
41.6%
Week of
Aug 24, 2026
Off-exch Lit
View
Smart Money
Insider Trades Cluster buy
Net (90d)
+$1.9M
Buyers / Sellers
3 / 0
Buyers Sellers
View
Congressional Trades Buy
Member
Gilbert Cisneros
Amount
$1.0K–$15.0K
Traded
Jun 5, 2026
View
Financials
Financials
Revenue (FY)
$4.1B
Net income (FY)
$374.9M
EPS diluted
$1.87
View
Buybacks
Authorized
$3.0B
Remaining
$1.5B
Spent Remaining
View
Filings
SEC Filings
Latest
8-K
Filed
Sep 9, 2026
This year
10
View
Proposed Sales
Value
$12.7M
Shares
115.0K
Filed
Sep 19, 2024
View
Earnings & Events
Webcasts
Last webcast
Sep 9, 2026
View

Performance

5D 20D 120D MTD YTD
COO +2.8% -19.4% -20.6% +0.7% -30.6%
SPY -0.2% -0.5% +12.2% +0.9% +12.9%
vs SPY +3.0% -19.0% -32.8% -0.3% -43.4%

Capital returns

Buyback program · as of Sep 9, 2026
Authorized
$3.00B
Spent (derived)
$1.50B
Remaining
$1.50B
Spent Remaining

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 711404 CUSIP 216648501 13F (30d) 18 filings 14 filers Visit website Investor relations